Compare ELWT & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELWT | ELTX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 45.6M |
| IPO Year | 2025 | 2014 |
| Metric | ELWT | ELTX |
|---|---|---|
| Price | $3.05 | $1.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 15.2K | ★ 303.3K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.37 | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,618,000.00 | $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $111.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.48 | N/A |
| 52 Week Low | $2.70 | $1.25 |
| 52 Week High | $9.72 | $16.00 |
| Indicator | ELWT | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 20.92 | 37.50 |
| Support Level | N/A | $1.25 |
| Resistance Level | $7.99 | $1.98 |
| Average True Range (ATR) | 0.50 | 0.19 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 8.53 | 28.12 |
Elauwit Connection Inc is a provider of broadband Internet networks for the multifamily and student housing property sector. It designs, installs, operates, and maintains new fiber-optic and WiFi networks throughout each contracted property. Once installed, property owners begin selling Internet connectivity over Elauwit's network directly to their residents at monthly prices and terms of their choosing. Elauwit, in turn, provides all resident activation, onboarding, customer support, and network monitoring and maintenance services in exchange for a fixed monthly fee based on the number of units in the property times a monthly per-unit wholesale price. Its contracts with property owners generally have five to eight-year terms. Geographically, the company mainly operates in the U.S.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.